Ablynx Builds Case For AbbVie Option On Humira Successor
Clinical data shows Ablynx's anti-IL 6R vobarilizumab (ALX0061) to have efficacy in the same range as Roche's Actemra as a monotherapy for rheumatoid arthritis. With more data due shortly, Ablynx is confident that AbbVie will exercise its option for the product.
You may also be interested in...
A major setback for Ablynx as AbbVie decides not to exercise its opt-in for vobarilizumab in rheumatoid arthritis. Though the competitive landscape of biologics targeting IL-6 casts a shadow over its commercial prospects, Ablynx is determined to continue development.
Deal Watch: AZ Ups mRNA Stake, Gilead's HIV Innovation, Hospira Returns Lucentis Biosimilar, Pfizer/Takeda End Distribution Deal
Deal activity over the past week saw AstraZeneca stealthily increase its commitment to mRNA player Moderna, Gilead seek innovation in HIV through an alliance with Genmab for its bispecific antibody technology, and Hospira back out of a licensing deal for Pfenex's Lucentis biosimilar, and more.
Galapagos NV, which suffered a major shock in September when AbbVie decided not to exercise its option on their JAK1 inhibitor filgotinib, has secured $725m up front from Gilead Sciences Inc. for the promising rheumatoid arthritis treatment.